Amgen and AstraZeneca’s IMDELLTRA-IMFINZI Improves SCLC Survival
Thousand Oaks, California, USA, September 8, 2026 Amgen and AstraZeneca have announced positive results from the Phase 3 DeLLphi-305...
SCLC
Advertisement
AbbVie Highlights Lung Cancer Pipeline Data at WCLC 2026
North Chicago, Illinois, USA, August 21, 2026 AbbVie has announced new clinical, translational and real-world research findings that will...
BioNTech Advances Lung Cancer Pipeline Ahead of WCLC 2026
MAINZ, Germany, August 20, 2026 BioNTech SE is set to highlight major progress across its lung cancer clinical development...
Zevra Therapeutics Publishes Four-Year MIPLYFFA Real-World NPC Data
BOSTON, Aug. 3, 2026 Zevra Therapeutics, Inc. announced the publication of four-year real-world safety and effectiveness data evaluating MIPLYFFA®...
Rocket Pharmaceuticals Reports Positive RP-A501 Safety Update
CRANBURY, N.J., Aug. 3, 2026 Rocket Pharmaceuticals, Inc. announced a positive clinical safety update from the first three patients...
Advertisements
Zai Lab Receives FDA Orphan Drug Designation for Zoci
SHANGHAI & CAMBRIDGE, Mass., Aug. 3, 2026 Zai Lab Limited announced that the U.S. Food and Drug Administration (FDA)...
Hansoh Pharma Reports Positive Phase III Ris-Rez SCLC Results
SHANGHAI, China, July 10, 2026 Hansoh Pharmaceutical Group Co., Ltd. has announced that its Phase III ARTEMIS-008 clinical trial...
Zai Lab Secures EMA Support for Rare Lung Cancer Therapy
SHANGHAI & CAMBRIDGE, Mass., June 16, 2026 Zai Lab announced that the European Medicines Agency (EMA) has granted Orphan...
Jazz Reports Phase 3 LAGOON Results for Zepzelca in SCLC
DUBLIN, Ireland, June 12, 2026 Jazz Pharmaceuticals has announced topline results from the Phase 3 LAGOON trial evaluating Zepzelca®...
SystImmune’s BL-M14D1 Shows Strong Activity in SCLC
REDMOND, Wash., June 1, 2026 SystImmune has reported encouraging Phase 1 clinical data for its investigational DLL3-targeting antibody-drug conjugate...
Advertisement
